Аборт

Екипът на Gynmed е силно ангажиран с допълнителното подобряване на законите и регулациите относно контрацепцията и аборта, както и на грижите и медицинското лечение на жените. За тази цел публикуваме нови открития. Следва списък със статии от медицински списания, в които са участвали от членове на екипа. Публикациите са на английски и немски език.

Abortion: legislation and statistics in Europe

The European Journal of Contraception & Reproductive Health Care, Christian Fiala, Aubert Agostini, Teresa Bombas, Roberto Lertxundi, Marek Lubusky, Mirella Parachini & Kristina Gemzell-Danielsson, 14. April 2022
Линк
Experiences of Women Accessing an Abortion Clinic Confronted by Religiously Motivated Demonstrators: A Pilot Study

PubMed, Christian Fiala, Johanna Özogul, Jennifer Kernreiter, 21. April 2020
Линк
Management of Very Early Medical abortion - An International Survey Among Providers

PubMed, Christian Fiala, Teresa Bombas, Mirella Parachini, Aubert Agostini, Roberto Lertxundi, Marek Lubusky, Laurence Saya, Kristina Gemzell Danielsson, 01. February 2020
Линк
Management of Pain Associated With up-to-9-weeks Medical Termination of Pregnancy (MToP) Using Mifepristone-Misoprostol Regimens: Expert Consensus Based on a Systematic Literature Review

PubMed, C Fiala, A Agostini, T Bombas, S Cameron, R Lertxundi, M Lubusky, M Parachini, L Saya, B Trumbic, K Gemzell Danielsson, 03. September 2019
Линк
Outcome of first trimester medical termination of pregnancy: definitions and management

Christian Fiala, Sharon Cameron, Teresa Bombas, Mirella Parachini, Aubert Agostini, Roberto Lertxundi, Marek Lubusky, Laurence Saya & Kristina Gemzell Danielsson, 02. January 2019
Pdf , 2.02 MB Линк
hCG Testing to Determine Outcome after Medical Abortion: A Review

J Preg Child Health , Christian Fiala, Teresa Bombas, Mirella Parachini, Aubert Agostini, Roberto Lertxundi, Marek Lubusky and Kristina Gemzell Danielsson, 2019
Pdf , 679.21 KB Линк
Pain management for up to 9 weeks medical abortion - An international survey among abortion providers.

Eur J Obstet Gynecol Reprod Biol. , Fiala C, Cameron S, Bombas T, Parachini M, Agostini A, Lertxundi R, Gemzell-Danielsson K., 2018
Pdf , 92.23 KB Линк
Early Medical Abortion - A Practical Guide For Healthcare Professionals

Editions de Santé, Dr Christian FIALA, Pr Aubert AGOSTINI, Dr Teresa-Alexandra CARMO-BOMBAS, Pr Kristina GEMZELL-DANIELSSON, Dr Roberto LERTXUNDI, Pr Marek LUBUSKY, Dr Mirella PARACHINI, 2018
Pdf , 1.47 MB
Efficacy and safety of very early medical termination of pregnancy: a cohort study.

PubMed, Bizjak I, Fiala C, Berggren L, Hognert H, Sääv I, Bring J, Gemzell-Danielsson K, 27. September 2017
Линк
There is no defense for ‘Conscientious objection’ in reproductive health care

Christian Fiala, Joyce H. Arthur, July 2017
Pdf , 510.53 KB Линк
Assessment of pain during medical abortion with home use of misoprostol.

PubMed, Cavet S, Fiala C, Scemama A, Partouche H, 22. June 2017
Линк
The dishonourable disobedience of not providing abortion.

PubMed, Arthur J, Fiala C, Gemzell Danielsson K, Heikinheimo O, Guðmundsson JA, 22. February 2017
Линк
Routine misoprostol before all surgical abortions.

PubMed, Cameron S, Fiala C, Gemzell-Danielsson K, November 2016
Линк
Yes we can! Successful examples of disallowing 'conscientious objection' in reproductive health care.

Fiala C, Gemzell Danielsson K, Heikinheimo O, Guðmundsson JA, Arthur J., 03. February 2016
Pdf , 750.07 KB
Medical Abortion beyond the 1st trimester

Editions de Santé, Kristina GEMZELL-DANIELSSON, Christian FIALA,  Aubert AGOSTINI,  Sharon CAMERON, Teresa BOMBAS, Roberto LERTXUNDI, Marek LUBUSKY, Mirella PARACHINI, 2016
Pdf , 6.68 MB
Clinical follow-up compared with self-assessment of outcome after medical abortion: a multicentre, non-inferiority, randomised, controlled trial.

PubMed, Oppegaard KS, Qvigstad E, Fiala C, Heikinheimo O, Benson L, Gemzell-Danielsson K, 21. February 2015
Линк
Sublingual versus vaginal misoprostol for cervical dilatation 1 or 3 h prior to surgical abortion: a double-blinded RCT  

Human Reproduction, Ingrid Saav; Helena Kopp Kallner; Christian Fiala; Kristina Gemzell-Danielsson, 2015
Линк
Instability of misoprostol tablets stored outside the blister: a potential serious concern for clinical outcome in medical abortion.

PubMed, Berard V, Fiala C, Cameron S, Bombas T, Parachini M, Gemzell-Danielsson K, 15. December 2014
Линк
Pain during medical abortion, the impact of the regimen: a neglected issue? A review.

PubMed, Fiala C, Cameron S, Bombas T, Parachini M, Saya L, Gemzell-Danielsson K., December 2014
Линк
Why We Need to Ban ‘Conscientious Objection’ in Reproductive Health Care

Joyce Arthur, Abortion Rights Coalition of Canada and Christian Fiala, Gynmed Clinic for Abortion and Family Planning, 14. May 2014
Линк
“Dishonourable disobedience” – Why refusal to treat in reproductive healthcare is not conscientious objection

Christian Fiala, Joyce H. Arthur, March 2014
Линк
Conscientious objection and induced abortion in Europe.

Eur J Contracept Reprod Health Care, Heino A, Gissler M, Apter D, Fiala C., August 2013
Линк
Is the introduction of anonymous delivery associated with a reduction of high neonaticide rates in Austria?

BJOG, Klier CM, Grylli C, Amon S, Fiala C, Weizmann-Henelius G, Pruitt SL, Putkonen H., 05. December 2012
Линк
Assessment of significant factors affecting acceptability of home administration of misoprostol for medical abortion

Contraception, Kopp Kallner H, Fiala C, Gemzell-Danielsson K., 85(4):394-7., April 2012
Линк
Effect of bacterial vaginosis on the pharmacokinetics of misoprostol in early pregnancy.

Hum Reprod., Sioutas A, Sandström A, Fiala C, Watzer B, Schweer H, Gemzell-Danielsson K., February 2012
Линк
Home self administration of vaginal misoprostol for medical abortion at 50-63 days compared with gestation of below 50 days

Hum Reprod., Kopp Kallner H, Fiala C, Stephansson O, Gemzell-Danielsson K., 25(5):1153-7, May 2010
Линк
Medical abortion in lactating women - low levels of mifepristone in breast milk

Acta Obstet Gynecol Scand., Sääv I, Fiala C,Hämäläinen JM, Heikinheimo O, Gemzell-Danielsson K., 89(5):618-22, May 2010
Линк
Providing Medical Abortion in Low-Resource Settings

Gynuity, 2009
Pdf , 88.55 KB
Evaluation of Early Medical Abortion (EMA) Pilot Sites

University of Southampton and Department of Health, London , Roger Ingham and Ellie Lee et al., 07. May 2008
Линк
Cervical priming with misoprostol prior to transcervical procedures

Int J Gynaecol Obstet., Fiala C, Gemzell-Danielsson K., Tang OS, von Hertzen H, 99 Suppl 2:S168-71, December 2007
Линк
Misoprostol for the termination of pregnancy up to 12 completed weeks of pregnancy

Int J Gynaecol Obstet., Faundes A, Fiala C, Tang OS, Velasco A., 99 Suppl 2:S172-7, December 2007
Линк
Misoprostol for intrauterine fetal death

Int J Gynaecol Obstet., Gómez Ponce de León R, Wing D, Fiala C, 99 Suppl 2:S190-3, December 2007
Линк
Misoprostol: first-line therapy for incomplete miscarriage in the developing world

BJOG, Gemzell-Danielsson K, Fiala C, Weeks A., 114(11):1337-9, November 2007
Линк
Pharmacokinetic profiles up to 12 h after administration of vaginal, sublingual and slow-release oral misoprostol

Hum Reprod., Aronsson A, Fiala C, Stephansson O, Granath F, Watzer B, Schweer H, Gemzell-Danielsson K., 22(7):1912-8, July 2007
Линк
Restricting access to safe abortion poses a serious health risk for women

ESC newsletter, ESC, European Society of Contraception: Expert Group on abortion - C. Fiala, Austria and C. Gemzell, Sweden, June 2007
Pdf , 438.62 KB
Review of medical abortion using mifepristone in combination with a prostaglandin analogue

Contraception, Fiala C, Gemzel-Danielsson K., 74(1):66-86, July 2006
Линк
Frequently asked clinical questions about medical abortion

WHO, 2006
Pdf , 200 KB Линк
Pharmacokinetics of a novel oral slow-release form of misoprostol

Hum Reproduction, Fiala C, Aronsson A, Granath F, Stephansson O, Seyberth HW, Watzer B, Gemzell-Danielsson K., 20(12):3414-8, December 2005
Линк
The effect of non-steroidal anti-inflammatory drugs (NSAIDs) on medical abortion with mifepristone and misoprostol at 13 to 22 weeks gestation

Human Reproduction, C. Fiala, ML. Swahn, O. Stephansson, and K. Gemzell-Danielsson, 20(11):3072-7, November 2005
Линк
Effects of slow release misoprostol on uterine contractility in early pregnancy

Human Reproduction, C. Fiala, A. Aronsson, O. Stephansson and K. Gemzell-Danielsson, 20(9):2648-52., September 2005
Линк
Abortion in Europe: Are the Laws and Practices patient centered?

Entre Nous magazine, UNFPA/ WHO No. 59, Christian Fiala, 23/5, 2005
Pdf , 28.86 KB
Acceptability of home-use of misoprostol in medical abortion

Contraception, Fiala C, Winikoff B, Helstrom L, Hellborg M, Gemzell-Danielsson K., 70(5):387-92., November 2004
Линк
Rh-prophylaxis in early abortion

Acta Obstet Gynecol Scand., Fiala C, Fux M, Gemzell Danielsson K., 82(10):892-903. Review, October 2003
Линк
Verifying the effectiveness of medical abortion; ultrasound versus hCG testing

Eur J Obstet Gynecol Reprod Biology, Fiala C, Safar P, Bygdeman M, Gemzell-Danielsson K., 109(2):190-5., 15. August 2003
Линк
Medical abortion - where we are in Europe

Entre Nous magazine, UNFPA/ WHO No 47-48, Christian Fiala, 16-17, September 2000

Abortion: legislation and statistics in Europe

Experiences of Women Accessing an Abortion Clinic Confronted by Religiously Motivated Demonstrators: A Pilot Study

Management of Very Early Medical abortion - An International Survey Among Providers

Management of Pain Associated With up-to-9-weeks Medical Termination of Pregnancy (MToP) Using Mifepristone-Misoprostol Regimens: Expert Consensus Based on a Systematic Literature Review

Outcome of first trimester medical termination of pregnancy: definitions and management

hCG Testing to Determine Outcome after Medical Abortion: A Review

Pain management for up to 9 weeks medical abortion - An international survey among abortion providers.

Early Medical Abortion - A Practical Guide For Healthcare Professionals

Efficacy and safety of very early medical termination of pregnancy: a cohort study.

There is no defense for ‘Conscientious objection’ in reproductive health care

Assessment of pain during medical abortion with home use of misoprostol.

The dishonourable disobedience of not providing abortion.

Routine misoprostol before all surgical abortions.

Yes we can! Successful examples of disallowing 'conscientious objection' in reproductive health care.

Medical Abortion beyond the 1st trimester

Clinical follow-up compared with self-assessment of outcome after medical abortion: a multicentre, non-inferiority, randomised, controlled trial.

Sublingual versus vaginal misoprostol for cervical dilatation 1 or 3 h prior to surgical abortion: a double-blinded RCT

Instability of misoprostol tablets stored outside the blister: a potential serious concern for clinical outcome in medical abortion.

Pain during medical abortion, the impact of the regimen: a neglected issue? A review.

Why We Need to Ban ‘Conscientious Objection’ in Reproductive Health Care

“Dishonourable disobedience” – Why refusal to treat in reproductive healthcare is not conscientious objection

Conscientious objection and induced abortion in Europe.

Is the introduction of anonymous delivery associated with a reduction of high neonaticide rates in Austria?

Assessment of significant factors affecting acceptability of home administration of misoprostol for medical abortion

Effect of bacterial vaginosis on the pharmacokinetics of misoprostol in early pregnancy.

Home self administration of vaginal misoprostol for medical abortion at 50-63 days compared with gestation of below 50 days

Medical abortion in lactating women - low levels of mifepristone in breast milk

Providing Medical Abortion in Low-Resource Settings

Evaluation of Early Medical Abortion (EMA) Pilot Sites

Cervical priming with misoprostol prior to transcervical procedures

Misoprostol for the termination of pregnancy up to 12 completed weeks of pregnancy

Misoprostol for intrauterine fetal death

Misoprostol: first-line therapy for incomplete miscarriage in the developing world

Pharmacokinetic profiles up to 12 h after administration of vaginal, sublingual and slow-release oral misoprostol

Restricting access to safe abortion poses a serious health risk for women

Review of medical abortion using mifepristone in combination with a prostaglandin analogue

Frequently asked clinical questions about medical abortion

Pharmacokinetics of a novel oral slow-release form of misoprostol

The effect of non-steroidal anti-inflammatory drugs (NSAIDs) on medical abortion with mifepristone and misoprostol at 13 to 22 weeks gestation

Effects of slow release misoprostol on uterine contractility in early pregnancy

Abortion in Europe: Are the Laws and Practices patient centered?

Acceptability of home-use of misoprostol in medical abortion

Rh-prophylaxis in early abortion

Verifying the effectiveness of medical abortion; ultrasound versus hCG testing

Medical abortion - where we are in Europe

Sublingual versus vaginal misoprostol for cervical dilatation 1 or 3 h prior to surgical abortion: a double-blinded RCT  